Skip to main content

Stock Review: GLENMARK PHARMA



THE phase-III trials for Crofelemer for cure of HIV-associated diarrhoea have been completed successfully. And that is good news for Glenmark Pharma, since the drug's development and commercialisation rights in select markets have been in-licensed by the company. The drug, whose launch in India and the rest of the world is subject to regulatory approvals, is touted to become the first novel drug launched by the company.


   The company's announcement came at a time when its stock is trading at almost a two-year high, riding on the wave of a stellar financial performance during the second quarter ended September 2010. Glenmark's stock gained 4.4% during the day and closed 3.6% up for the day.


   Crofelemer is a first-in-class anti-diarrhoeal drug. Glenmark's partners — US-based Napo Pharmaceuticals and Salix Pharmaceuticals — have announced the completion of phase-III trials for the drug in the US. Glenmark has in-licensed the developing and marketing rights to the drug in 140 emerging markets, including India, for multiple diarrhoea indications. The company also has the exclusive rights to supply the active pharmaceutical ingredient for the drug globally, except China.


   Using the clinical studies conducted in the US, Glenmark is looking at seeking approval for the drug in India by 2012. It, typically, takes about two years post approval to achieve peak sales of the drug. Glenmark is looking at a peak sales opportunity of about Rs 400 crore across all the 140 markets by 2014-2015. The company, depending on how attractive the research findings are, can extend the launch of the drug for treating other kinds of diarrhoea indications like adult diarrhoea, paediatric diarrhoea, etc.


   This is good news for the company, but investors should be cautioned against bearing too much enthusiasm too early in the day. The monetary gains of this development will start trickling in only after two years from now. Moreover, achieving the peak sales opportunity is two years away. Investors must keep in mind that benefits from innovative R&D are not low-hanging fruits. It involves long gestation and execution risks, too. Though after a series of setbacks and out-licensing deals, Glenmark has finally got a novel drug at the final stage, it is still not advisable to discount all the estimated peak sales from its launch into the present valuations of the company – especially when it is the first-ofits-kind launch for the company.

Popular posts from this blog

Birla SunLife FTP Series Dividend

Download Tax Saving Mutual Fund Application Forms Invest In Tax Saving Mutual Funds Online Buy Gold Mutual Funds Leave a missed Call on 94 8300 8300   Birla SunLife Mutual Fund Dividend   Birla Sun Life Mutual Fund has announced dividend under the dividend option of Birla SL FTP Series GY Reg-D , Birla SL FTP Series GY Reg-DQ , Birla SL FTP Series GY Direct-D and Birla SL FTP Series DA-D .   The quantum of dividend will be the entire distributable surplus as on the record date. The record date has been fixed as May 08, 2014. For further information contact Prajna Capital on 94 8300 8300 by leaving a missed call Leave a missed Call on 94 8300 8300 Leave your comment with mail ID and we will answer them OR You can write back to us at PrajnaCapital [at] Gmail [dot] Com ---------------...

Mutual Fund Review: Kotak Opportunities

    DESPITE a portfolio of around 57 stocks, a large-cap tilt and exposure to derivatives, debt and cash, it is not a fund for the cautious. True to its calling, it scouts for opportunities and doesn't hesitate in taking concentrated sector and stock bets. This leads to extreme returns. In the bull phase (June 15, 2006 to January 8, 2008), it delivered 91.26 per cent against the 81.29 per cent average of other opportunity funds. Unsurprisingly, it shed higher in the bear hug of 2008. While in the recent run up (March 9, 2009 to June 30, 2010) it delivered 85 per cent against its peers 87 per cent. Its charm lies in its capability to identify sector trends ahead of time. In 2005, it rode the FMCG wave and the move paid off. In the first quarter of 2006, it focused on metals. In 2007, its exposure to construction and metals that resulted in a superb performance. In 2008, it was overweight on the least-hit FMCG sector, which helped it get away with an average fall. More recently...

How to invest in the Stock Markets?

Invest In Tax Saving Mutual Funds Online Download Tax Saving Mutual Fund Application Forms Buy Gold Mutual Funds Call 0 94 8300 8300 (India)   One of the trickiest things in life is making a decision when to enter and exit the stock market. Investing in the stock markets is all about timing. Yet the timing is never right .Stocks never seem to reach the optimum price one wants .When share prices are expected to fall down to abysmal levels they rise and are soon out of one’s price range. When share prices are at low levels one keeps waiting for them to hit rock bottom and when they rise one has missed the bus. Stock markets are all about keeping one’s emotions in check. One must stand the true test of time.   What are interest rate sensitive stocks? When interest rates rise consumers who purchase expensive items such as cars on credit might postpone them. Discretionary spending is cut .Customers might postpon...

ASBA Option for Initial Public Offer (IPO)

IPO (initial public offering) applicants, particularly the unsuccessful ones, often have to face a double whammy of sorts. On the one hand they fail to get allotment of shares and on the other, they lose out on the interest during the period their money is locked —that is, if they have opted for the traditional method of issuing cheques for depositing the application money. However, if they choose the ASBA (Application Supported by Blocked Amount) facility, they can circumvent this problem. But do note that you cannot decide to make two applications – one by way of cheque payment and the other through ASBA. If you do so, it could be rejected on the grounds that it constitutes multiple applications. Introduced by Securities and Exchange Board of India ( Sebi ) in 2008, using ASBA has become mandatory for all non-retail investors. Retail investors, though, continue to have the option of choosing between the old and new mechanisms. However, it is in your interest to opt for ASBA. He...

SBI Emerging Businesses

Invest In Tax Saving Mutual Funds Online Download Tax Saving Mutual Fund Application Forms Buy Gold Mutual Funds Call 0 94 8300 8300 (India)   We like this scheme for the assumed risks it takes by investing in emerging business themes based on exports and outsourcing for which it has been handsomely rewarded.   Strategy Although the fund watches out for the opportunities in sectors based on general economic patterns, its concentrated exposure to certain sectors makes it similar to sector funds. According to the fund manager, there is no restriction on buying stocks as long as the valuation comfort exists. Since 2009, this fund has also increased its exposure to small-cap allocation that went up from an average 24.8 per cent in 2008 to an average of about 45 per cent as of now. The average market capitalisation of this fund is Rs 7,361 crore, which is on the lower band in the category. This fund restricts investm...
Related Posts Plugin for WordPress, Blogger...
Invest in Tax Saving Mutual Funds Download Any Applications
Transact Mutual Funds Online Invest Online
Buy Gold Mutual Funds Invest Now